reports
- ABGSC Healthcare Research
- Morten Larsen
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
FME FRESENIUS MEDICAL CARE AG
EDEN EDENRED SA
DBK DEUTSCHE BANK AG
ULVR UNILEVER PLC
MMK MAYR-MELNHOF KARTON AG
PHIA KONINKLIJKE PHILIPS N.V.
GEBN GEBERIT AG
NXT NEXT PLC
RY4C RYANAIR HOLDINGS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EVK EVONIK INDUSTRIES AG
COLO B COLOPLAST A/S CLASS B
SNP PETROM S.A.
BP. BP P.L.C.
BIM BIOMERIEUX SA
TEF TELEFONICA SA
BNTX BIONTECH SE
AMRZ AMRIZE AG
AAL ANGLO AMERICAN PLC
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
FME FRESENIUS MEDICAL CARE AG
EDEN EDENRED SA
DBK DEUTSCHE BANK AG
ULVR UNILEVER PLC
MMK MAYR-MELNHOF KARTON AG
PHIA KONINKLIJKE PHILIPS N.V.
GEBN GEBERIT AG
NXT NEXT PLC
RY4C RYANAIR HOLDINGS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EVK EVONIK INDUSTRIES AG
COLO B COLOPLAST A/S CLASS B
SNP PETROM S.A.
BP. BP P.L.C.
BIM BIOMERIEUX SA
TEF TELEFONICA SA
BNTX BIONTECH SE
AMRZ AMRIZE AG
AAL ANGLO AMERICAN PLC
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%.• EBIT1,2 was DKK 7,670 million, a 5% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.• Adjusted3 net profit before special items was DKK 5,148 million, a DKK 12...
Coloplast A/S - Årsregnskabsmeddelelse 2024/25
Coloplast A/S - Årsregnskabsmeddelelse 2024/25 2024/25Årsregnskabsmeddelelse 1. oktober 2024 - 30. september 2025 Organisk vækst på 7% og en overskudsgrad1 på 28% i 4. kvartal. Den rapporterede omsætning i danske kroner steg 0%, negativt påvirket af valutaudviklingen samt frasalget af hudplejeforretningen.• Organisk vækst pr. område: Stomi 7%, Kontinens 9%, Stemme og Respiratorisk Pleje 9%, Wound & Tissue Repair 5% og Urologi 2%.• Væksten i Stomi var bredt funderet, med et godt bidrag fra nylige produktlanceringer og drevet af Europa og Øvrige markeder ex. Kina. Salget i Kina fa...
Coloplast A/S - Full-Year Financial Results 2024/25
Coloplast A/S - Full-Year Financial Results 2024/25 2024/25Full year financial results 1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%.• Growth in Ostomy Care was broad based with good contribution from recent product launches and led by Europe and Emerging Markets ex. China. ...
Icelandic Salmon - Invitation to presentation of the third quarter 202...
Icelandic Salmon - Invitation to presentation of the third quarter 2025 results Bíldudalur, 3 November 2025 Icelandic Salmon will present its third quarter 2025 results on Thursday, 6 November 2025, via a Teams webinar in English. To register, please email . A link will be distributed before the webinar begins. CEO Bjørn Hembre and Interim CFO Edvin Aspli will present the results at 09:00 Icelandic time (10:00 CET). A Q&A session will follow, with questions taken at the end of the webinar. One-on-one meetings can be arranged on Teams following the webinar. If interested, please send an e...
- Alexander Aukner
- ABGSC Healthcare Research
- Morten Larsen
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
- ABGSC Online Gaming Research
- Nikola Kalanoski
- Simon Jönsson
- ABGSC Online Gaming Research
- Nikola Kalanoski
- Simon Jönsson
- Alexander Aukner
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conferenc...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET Tuesday, 4 November 2025 at 11:00 - 12:00am CETIn connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the ...
- ABGSC Healthcare Research
- Morten Larsen
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
- Alexander Aukner
LSG LEROY SEAFOOD GROUP ASA
AUSS AUSTEVOLL SEAFOOD ASA
AKVA AKVA GROUP ASA
SALM SALMAR ASA
GSF GRIEG SEAFOOD ASA
MOWI MOWI ASA
BAKKA BAKKAFROST P/F
SALMOCAM SALMONES CAMANCHACA SA
IFISH ICE FISH FARM AS
ASA ATLANTIC SAPPHIRE
SALME SALMON EVOLUTION HOLDING
KING THE KINGFISH COMPANY NV
AKBM AKER BIOMARINE
ISLAX ARNARLAX AS
AFISH ARCTIC FISH HOLDING AS
MAS MÅSØVAL
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den k...
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Selskabsmeddelelse nr. 09/2025Intern viden Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Interim CEO Lars Rasmussen har i dag informeret Coloplasts bestyrelse om, at han ikke genopstiller som bestyrelsesmedlem ved den kommende ordinære generalforsamling den 4. december 2025. ”På vegne af bestyrelsen vil jeg gerne takke Lars for hans mangeårige engagement i Coloplast. Gennem næsten fire årtiers virke – herunder 10 år som CEO og...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.